Lund Arthritis Research Group (LARG)
1 – 10 of 86
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor : results from 13 European registries
(
- Contribution to journal › Article
-
Mark
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs : a Swedish nationwide study (COVID-19-REUMA)
(
- Contribution to journal › Article
-
Mark
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
(
- Contribution to journal › Article
-
Mark
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
(
- Contribution to journal › Article
-
Mark
Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota
2024) In ACR Open Rheumatology(
- Contribution to journal › Article
- 2023
-
Mark
Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis : A Decision Tree Analysis by Indication
(
- Contribution to journal › Article
-
Mark
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: Data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
(
- Contribution to journal › Article
-
Mark
Healthcare professionals' perceptions of working on lifestyle management for patients with early rheumatoid arthritis - a qualitative study
2023) In International Journal of Qualitative Studies on Health and Well-being 18(1). p.2241225-2241225(
- Contribution to journal › Article
-
Mark
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
(
- Contribution to journal › Scientific review
-
Mark
Citrullination of C1-inhibitor as a mechanism of impaired complement regulation in rheumatoid arthritis
(
- Contribution to journal › Article